1.Basic conditions of skin in female consumers for cosmetics in Chengdu area
Fengwei CHENG ; Xi WANG ; Honghai LI ; Galzote CARLOS ; Li LI
Chinese Journal of Medical Aesthetics and Cosmetology 2012;(5):360-363
Objective To investigate the skin basic conditions of normal female consumers for cosmetics who use a cream of lower than RMB 25 yuan in markets in Chengdu area.Methods Female subjects aged 25 to 45 years were recruited in Chengdu and divided into four age groups.Parameters were noninvasively tested to investigate skin baseline conditions of the two groups,including skin moisturization,trans-epidermal water loss (TEWL),color,texture and pH etc.Meanwhile,subjective scores were acquired by experienced dermatologists and self-questionnaires were collected to investigate subjects' concerns.Results Skin texture,softness,and skin color were found significantly different between age groups.The top 3 skin problems were dryness,skin color and wrinkles; the top 3 ideal skin were moisture,shining and fairness.Conclusions With similar environment and skin care habits,35-year-old is a turning point for females of decreased metabolism in the skin,as seen from skin color,elasticity,and roughness.
2.A comparative study on conbercept and triamcinolone acetoinde intravitreal injection for macular edema secondary to central retinal vein occlusion
Fengwei, MA ; Cuiyun, DU ; Meihong, CHENG ; Yusheng, MA
Chinese Journal of Experimental Ophthalmology 2016;34(9):837-841
Background Macular edema is one of the serious complications of central retinal vein occlusion (CRVO),and the present therapies are laser coagulation and intravitreal injection of anti-vascular endothelial growth factor(VEGF)drugs.Conbercept is humanized-monoclonal VEGF antibody and used for the treatment of retinal vascular diseases.However,fewer studies were focused on its application in macular edema secondary to CRVO.Objective The aim of this study was to compare the effectiveness and safety of conbercept with triamcinolone acetonide(TA)by intravitreal injections for macular edema secondary to CRVO. Methods A non-randomized controlled study was carried out under the approval of the informed consent of patients.Sixty eyes of 60 patients with macular edema secondary to CRVO were included in Weifang Yidu Central Hospital from March 2012 to August 2013.The eyes were divided into the conbercept group and TA group with 30 for each group.Conbercept and TA of 0.05 ml were intravitreally injected in different groups,and the best corrected visual acuity(BCVA),central macular thickness(CMT)measured by OCT,intraocular pressure(IOP)and relavant complications were examined before injection and 1 week,1 month,3 months and 6 months after injection.The treatment outcomes were compared intergrouply and along with time. Results The BCVA was evidently better in 1 week,1 month,3 months and 6 months after injection than that before injection both in conbercept group and TA group(all at P<0.01),and the BCVA of TA group was better than that of conbercept group 1 week after injection(P<0.05).The CMT values of Conbercept were(572.00± 100.01),(325.12±91.55),(280.00±92.37),(258.65 ±88.65),(300.00±87.64)μm,and those of TA group were(570.00± 102.21),(345.12±89.31),(290.00±80.27),(309.65 ±84.13)and(303.00±90.59)μm,and CMT value after injection was significantly lower in 1 week,1 month,3 months and 6 months after injection than that before injection both in the conbercept group and the TA group(all at P<0.05),and CMT value was evidently reduced in the conbercept group compared with the TA group 3 months after injection(P<0.05).The IOP was(15.20±3.52),(21.20±3.80),(26.40±4.00),(23.60±3.73)and(21.50±3.27)mmHg in the TA group before injection and 1 week,1 month,3 months and 6 months after injection,showing significnatly elavation after injection(all at P<0.05),and the IOP at different time points was higher in the TA group than that in the conbercept group(all at P<0.05).However,there was no considerable change of IOP before and after injection in conbercept group(all at P<0.05). Conelutions Both conbercept and TA are effective for macular edema secondary to CRVO by intravtreal injection.Compared with TA,conbercept is much safer because of less risk of IOP rising after intravtreal injection.
3.Effects of electroacupuncture on the expression of cholesterol reverse transport receptors in peritoneal mcrophages of atherosclerotic rabbits
Haiyan LUAN ; Xiaozhe TONG ; Shaoning ZHANG ; Yingying ZHAO ; Fengwei JIANG ; Hui LI ; Jingshu HAN ; Zedong CHENG ; Jingyuan LI
Journal of Beijing University of Traditional Chinese Medicine 2024;47(7):1005-1011
The objective of this study was to examine the effects of electroacupuncture on the expression of ATP-binding cassette transporter A1(ABCA1),ATP-binding cassette transporter G1(ABCG1),and class B type Ⅰ scavenger receptor(SR-B Ⅰ)genes and proteins in peritoneal macrophages of atherosclerotic rabbits.The study aimed to explore the mechanism underlying the treatment of atherosclerosis(AS)with electroacupuncture.Methods Twenty-six male New Zealand rabbits were randomly divided into the negative control group(n=7)and the modeling group(n=19)using a random number table method.The negative control group rabbits were fed a regular diet,while the modeling group was induced with a combination of high-fat feed and common carotid artery balloon injury surgery to create an AS model.After successful modeling,the rabbits in the modeling group were further divided into the model group,the electroacupuncture group,and the atorvastatin group,with 6 rabbits in each group.The rabbits in the electroacupuncture group received electroacupuncture at"'Neiguan'(PC6)","'Zusanli'(ST36)",and"'Guanyuan'(ST25)"acupoints,using a density wave,a current of 1 mA,and a frequency of 4 Hz/20 Hz,once a day.The needle was retained for 20 minutes each time,and a total of 4 courses of treatment were conducted,with 6 days per course.The rabbits in the atorvastatin group were administered atorvastatin calcium tablet suspension(1 mg/kg)orally once a day,for 6 days per course,with a total of 4 courses.After the interventions,HE staining was performed to observe the morphological changes in the common carotid artery tissue of the rabbits.Peritoneal macrophages were collected from the rabbits,and the mRNA expression levels of ABCA1,ABCG1,and SR-B Ⅰ were measured using real-time fluorescence PCR.The protein expression levels of ABCA1,ABCG1,and SR-B Ⅰ were detected using Western blotting.Results The negative control group exhibited smooth intima of common carotid artery in rabbits,while the model group displayed damaged intima of common carotid artery,thickened artery walls,and the formation of atherosclerotic plaques.The electroacupuncture group and atorvastatin group showed significant improvements in wall thickening and a reduction in plaque area.Compared with the negative control group,the mRNA and protein expressions of ABCA1,ABCG1,and SR-B Ⅰ in peritoneal macrophages of rabbits in the model group were reduced(P<0.01).Compared with the model group,the electroacupuncture group and atorvastatin group exhibited increased mRNA and protein expressions of ABCA1,ABCG1,and SR-B Ⅰ in abdominal macrophages of rabbits(P<0.01).Furthermore,the atorvastatin group demonstrated increased mRNA levels of ABCG1 and SR-B Ⅰ,as well as increased protein expressions of ABCA1,ABCG1,and SR-B Ⅰ in peritoneal macrophages of rabbits,in comparison to the electroacupuncture group(P<0.01).Conclusion Electroacupuncture can enhance the expressions of ABCA1,ABCG1,and SR-B Ⅰ mRNA and protein in abdominal macrophages of AS rabbits,thereby promoting the process of cholesterol reverse transport.This may be one of the mechanisms underlying the effectiveness of acupuncture in the treatment of AS.
4.Pharmacokinetic Study on Single and Multiple Administration of Gefitinib Emulsion in Rats
Ying LI ; Zhou WEN ; Fengwei MA ; Zhigang LIU ; Chi TIAN ; Zhifang LIU ; Zeneng CHENG
China Pharmacy 2020;31(1):48-52
ABSTRACT OBJECTIVE:To study pharmacokinetic characteristics of single dose and multiple dose administration of Gefitinib emulsion in rats. METHODS:The rats were divided into single administration group and multiple administration group. Single administration group was subdivided into Gefitinib raw medicine group(50 mg/kg,i.g.)and Gefitinib emulsion group(50 mg/kg,i.g.),with 6 rats in each group,gavage once. Multiple administration group were subdivided into Gefitinib raw medicine group (50 mg/kg)and Gefitinib emulsion group(50 mg/kg),with 8 rats in each group;they were given relevant medicine intragastricaly for consecutive 7d,once a day. 0.3 mL blood of rats in Gefitinib raw medicine group was taken before medication and 1,2,2.5, 3,3.5,3.75,4,4.25,4.5,6,8,12 and 24 h after medication;0.3 mL blood of rats in Gefitinib emulsion group was taken before medication and 2,4,6,8,9,10,11,12,13,14,16,24,36 and 48 h after administration(Multiple administration group is after 7 d of administration). HPLC method was used to determine the plasma concentration of gefitinib in rat,and plasma concentration-time curves were drawn. Pharmacokinetic parameters were fitted by using DAS 2.0 software. RESULTS:After single administration,compared with the tmax([ 2.67±0.75)h],MRT0-24 h ([ 8.68±0.91)h],MRT0- ∞ ([ 14.20±3.45)h] of Gefitinib raw medicine group,tmax ([ 8.33±4.41)h],MRT0-48 h ([ 15.00±1.60)h],MRT0-∞ ([ 17.60±2.66)h] of Gefitinib emulsion group were increased significantly(P<0.05). After multiple administration,compared with the tmax ([ 6.79±3.75)h],AUC0-48 h ([ 41.10±8.92) mg·h/L],Vz/F [(16.30±5.45)L/kg],CLz/F [(0.94±0.19) L/(h·kg)],MRT0-48 h ([ 10.10 ± 0.36) h] of Gefitinib raw medicine group,Vz/F [(44.20±30.3)L/kg],CLz/F[(1.89± 1.56) L/(h·kg)],MRT0-48 h ([ 16.20 ± 2.52) h] of Gefitinib emulsion group were increased significantly (P<0.05) AUC0-48 h ([ 38.70±26.20)mg·h/L] was decreased significantly (P<0.05),and tmax ([ 10.40±3.25)h] was increased,without statistical significance. CONCLUSIONS: Compared with Gefitinib raw medicine,single and multiple administration of Gefitinib emulsion can effectively prolong the peak time,the results of this study can provide reference for new delivery system study of Gefitinib.